| abstract |
The process for producing (1S, 4R) - or (1R, 4S) -4- (2-amino-6-chloro-9-H-purin-9-yl) -2-cyclopentene-1-methanol of formulas I and II. In the first step, (. + -.) - 2-azabicyclo [2.2.1] -hept-5-en-3-one of formula III is acylated to a derivative of (. + -.) - 2-azabicyclo [2.2.1] hept-2-azabicyclo [2.2.1] heptane. 5-en-3-one of formula IV. This is reduced to a cyclopentene derivative of formula V in the second step, which in the third stage biotechnologically converts to (1R, 4S) - or (1S, 4R) -1-amino-4- (hydroxymethyl) -2-cyclopentene of formula VI, VII This is converted in the fourth step by means of N- (2-amino-4,6-dichloropyrimidin) -5-yl) formamide of formula VIII to (1S, 4R) - or (1R, 4S) -4 - [(2 -amino-6-chloro-5-formamido-4-pyrimidinyl) amino] -2-cyclopentene-1-methanol of formula IX, X and the latter compound are cyclized to the final product of formula I or II in the fifth step. |